Cannabis Bioscience International Holdings (CBIH) Debt to Equity (2023 - 2026)

Cannabis Bioscience International Holdings has disclosed Debt to Equity across 4 years of filings, most recently posting -$0.18 for Q1 2026.

• Debt to Equity for Q1 2026 came in at -$0.18, up 31.64% year-over-year; the trailing twelve-month figure through Feb 2026 was -$0.18 (up 31.64% YoY), and the FY2025 annual result was -$0.23, up 1.79% from the prior year.
• Debt to Equity came in at -$0.18 for Q1 2026 at Cannabis Bioscience International Holdings, up from -$0.19 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of -$0.18 in Q1 2026 to a low of -$0.45 in Q2 2023.
• The 4-year median for Debt to Equity is -$0.23 (2024), against an average of -$0.25.
• Across the five-year window, Debt to Equity surged 48.22% in 2024 and declined 0.18% in 2025, its largest moves.
• Cannabis Bioscience International Holdings' Debt to Equity stood at -$0.31 in 2023, then advanced by 25.1% to -$0.23 in 2024, then rose by 16.75% to -$0.19 in 2025, then gained by 7.08% to -$0.18 in 2026.
• The last three Debt to Equity figures came in at -$0.18 (Q1 2026), -$0.19 (Q4 2025), and -$0.2 (Q3 2025), per Business Quant data.